1. Home
  2. OBIO vs BWAY Comparison

OBIO vs BWAY Comparison

Compare OBIO & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OBIO

Orchestra BioMed Holdings Inc.

N/A

Current Price

$5.94

Market Cap

473.0M

Sector

Health Care

ML Signal

N/A

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

N/A

Current Price

$10.25

Market Cap

468.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OBIO
BWAY
Founded
2017
2003
Country
United States
Israel
Employees
86
N/A
Industry
Medicinal Chemicals and Botanical Products
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
473.0M
468.5M
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
OBIO
BWAY
Price
$5.94
$10.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
3
Target Price
$12.43
★ $19.27
AVG Volume (30 Days)
★ 410.5K
101.5K
Earning Date
11-10-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 33.13
N/A
EPS
N/A
★ N/A
Revenue
★ $33,482,000.00
N/A
Revenue This Year
N/A
$33.61
Revenue Next Year
$40.42
$23.01
P/E Ratio
★ N/A
$81.98
Revenue Growth
★ 1169.22
N/A
52 Week Low
$3.46
$10.21
52 Week High
$6.50
$26.63

Technical Indicators

Market Signals
Indicator
OBIO
BWAY
Relative Strength Index (RSI) 54.73 38.54
Support Level $5.54 N/A
Resistance Level $6.49 $12.12
Average True Range (ATR) 0.40 0.59
MACD 0.02 -0.00
Stochastic Oscillator 70.97 3.43

Price Performance

Historical Comparison
OBIO
BWAY

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: